SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Aardvark Adventures -- Ignore unavailable to you. Want to Upgrade?


To: ~digs who wrote (1856)12/9/2005 5:09:39 AM
From: ~digs  Read Replies (2) | Respond to of 7944
 
SHOE @ 6.66
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
Shoe Pavilion, Inc. operates as an independent off-price footwear retailer that offers a range of women’s, men’s, and children’s designer label and name brand merchandise. As of March 21, 2005, the company operated 84 retail stores under the trade name Shoe Pavilion located in strip malls, outlet centers, and downtown locations in California, Washington, Oregon, and Arizona. It also offers its products through the Internet.

PBIO @ 4.950
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
Pressure BioSciences, Inc. (PBI), an early-stage company, focuses on the development of a technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between various levels to control bio-molecular interactions. The company, utilizing its PCT technology, researches, develops, and commercializes products for the control of bio-molecular interactions. Its products primarily include Barocycler NEP 2017, an instrument that is designed as a front-end sample preparation tool for genomic and proteomic systems; Barocycler NEP 3229, which is a lightweight, portable instrument designed to fit on a laboratory bench top, inside a biological safety cabinet, or on the shelf of a cold room; and PULSE tubes that transmit the power of PCT from the Barocycler instruments to the sample. PBI holds 13 US and 4 foreign patents covering multiple applications of PCT in the life sciences field, including areas, such as genomic and proteomic sample preparation, pathogen inactivation, control of enzymes, immunodiagnostics, and protein purification. It also owns a 30% investment in Source Scientific, LLC, which is an instrumentation company that develops and manufactures PBI’s PCT equipment. In addition, the company owns a passive investment in V.I. Technologies, Inc., formerly Panacos Pharmaceuticals, Inc., which is an antiviral drug discovery and development company.

[QEE] QUEENSTAKE RES LT › 0.20
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
Queenstake Resources, Ltd. operates as a gold mining and exploration company. It engages in the mining, processing, production, and sale of gold. The company owns a 100% interest in Jerritt Canyon gold mine that is located 50 miles north of Elko, Nevada. Jerritt Canyon is an operating gold complex with four producing underground mines and a 1.5 million ton per year capacity processing plant.

CASA @ 10.93 .. n52wh
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
Mexican Restaurants, Inc., through its subsidiaries, engages in the operation and franchise of Mexican-theme restaurants in the United States. The company operates its restaurants under various names: Casa Ole, Monterey's Tex-Mex Cafe, Monterey's Little Mexico, Tortuga Coastal Cantina, La Senorita, and Crazy Jose.

[ILGN.OB] INTERLEUKIN GENET › 4.39
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
Interleukin Genetics, Inc., a personalized healthcare company, primarily engages in the development and marketing of genetic risk assessment tests in the United States. It markets a genetic risk assessment test, PST, which identifies patients at risk for rapid progression of periodontitis, a bacterially induced chronic inflammation. The company also develops various preventive nutritional products and personalized therapeutics focusing on cardiovascular disease, osteoporosis, rheumatoid arthritis, endometriosis, periodontal disease, and weight management.

update: [URIX.OB] URANIUM RESOURCES › 0.76
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G



To: ~digs who wrote (1856)12/9/2005 12:31:46 PM
From: richardred  Read Replies (2) | Respond to of 7944
 
The thing I like about the company. I can get local press, right near Buffalo. I like the product mix. Selling high tech products to low tech industries.
Bad thing is. The stock is easily manipulated and not very liquid. Depending on future performance. It can turn into a good thing. Institutional ownership is low. Therefore IMO technicals will be for traders. Do to the factors, I mentioned. I believe Fundamentals will drive Institutional ownership towards this stock. Leading it higher if there continues to be quarter to quarter improvement.

I'm hoping!

BTW- I've been a long term holder of PTIE. There has been a pull back from its breakout due to factor concerning FDA approval of it's new product. All things considered. I still feel the product has a more than a good chance for approval. Considering Oxycontinen is already an approved product. IMO- The FDA focus should be on the product not easily being abused as compared to Oxycontinen.